Zobrazeno 1 - 10
of 67
pro vyhledávání: '"J. L. Callejas-Rubio"'
Autor:
R Bravo Marques, V Becerra Munoz, A J Walls Rodriguez, F Espildora Hernandez, J L Callejas Rubio, J I Morgado Garcia De Polavieja, I Martin Suarez, J L Bonilla Palomas, F Rivas-Ruiz, A Recio Mayoral
Publikováno v:
European Heart Journal. 43
Background Pulmonary arterial hypertension (PAH) is a syndrome characterized by marked remodeling of the pulmonary vasculature and leading to right heart failure and death. Selexipag, an oral prostacyclin IP receptor agonist, has been shown to decrea
Autor:
D. Gonzalez Serna, C. Shi, M. Kerick, J. Hankinson, J. Ding, A. McGovern, M. Tutino, N. Ortego, J. L. Callejas-Rubio, J. Martin Ibanez, G. Orozco
Publikováno v:
Annals of the Rheumatic Diseases. 81:74-75
BackgroundSystemic sclerosis (SSc) is a complex autoimmune disease with a strong genetic component. However, the underlying mechanism by which genetics increase disease risk is still unknown. The most recent GWAS studies have identified 27 independen
Autor:
J. Sanchez-Martin, J. Loricera, C. Moriano, S. Castañeda, J. Narváez, V. Aldasoro, O. Maiz, R. Melero, I. Villa-Blanco, P. Vela-Casasempere, S. Romero-Yuste, J. L. Callejas-Rubio, E. De Miguel, E. Galíndez-Agirregoikoa, F. Sivera, C. Fernández-López, C. Galisteo, I. Ferraz-Amaro, L. Sanchez-Bilbao, M. Calderón-Goercke, J. L. Hernández Hernández, M. A. González-Gay, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:698-699
BackgroundTocilizumab (TCZ) is the only biologic drug approved in giant cell arteritis (GCA), based in two clinical trials (CT) (1,2). CT included selected patients who may differ from those of clinical practice (CP). A high proportion of GCA patient
Autor:
L. Sanchez-Bilbao, J. Loricera, R. Melero, S. Castañeda, C. Moriano, I. Ferraz-Amaro, J. Narváez, V. Aldasoro, O. Maiz, I. Villa-Blanco, P. Vela-Casasempere, S. Romero-Yuste, J. L. Callejas-Rubio, E. De Miguel, E. Galíndez-Agirregoikoa, F. Sivera, C. Fernández-López, C. Galisteo, J. Sanchez-Martin, M. Calderón-Goercke, J. L. Hernández, M. A. González-Gay, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:689-690
BackgroundLarge vessel involvement in Giant Cell Arteritis (GCA), especially the aorta and/or its main branches, is frequent. Tocilizumab (TCZ) has shown efficacy and safety in GCA and other large-vessel vasculitis (1-4).ObjectivesTo assess the effic
Autor:
D. Prieto-Peña, J. Loricera, S. Castañeda, C. Moriano, P. Bernabéu, P. Vela-Casasempere, J. Narváez, V. Aldasoro, O. Maíz, C. Fernández-López, M. Freire González, R. Melero, I. Villa-Blanco, B. González-Alvarez, R. Solans-Laqué, J. L. Callejas-Rubio, C. Fernández-Díaz, E. Rubio Romero, S. García Morillo, M. Minguez, C. Fernández-Carballido, E. De Miguel, J. Sanchez-Martin, E. Fernández, S. Melchor, E. Salgado-Pérez, B. Bravo, S. Romero-Yuste, E. Galíndez-Agirregoikoa, F. Sivera, I. Ferraz-Amaro, C. Hidalgo, C. Romero-Gómez, C. Galisteo, P. Moya, N. Alvarez-Rivas, J. Mendizabal, J. C. Nieto González, J. R. De Dios, J. L. Andreu, I. Pérez de Pedro, M. Revenga, J. L. Alonso Valdivieso, R. M. Rosa, I. De la Morena, N. Fernández-Llanio, E. Labrador, J. A. Roman-Ivorra, F. Ortiz-Sanjuán, A. García-Valle, A. Gallego, C. Iñiguez, N. Garrido-Puñal, R. De la Torre, R. López-González, P. Collado, E. Raya, F. Navarro, A. J. Mas, C. Ordás, M. D. Boquet, M. L. Velloso Feijoo, C. Campos Fernández, I. Rúa-Figueroa, A. Conesa, S. Manrique Arija, M. A. González-Gay, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:691-692
BackgroundTocilizumab (TCZ) has shown to be effective for large vessel vasculitis including giant cell arteritis (GCA) and Takayasu arteritis (TAK) (1-5). However, LVV-GCA and TAK show different demographic and clinical features that may influence on
Autor:
J. Sanchez-Martin, J. Loricera, S. Castañeda, C. Moriano, J. Narváez, V. Aldasoro, O. Maiz, R. Melero, I. Villa-Blanco, P. Vela-Casasempere, S. Romero-Yuste, J. L. Callejas-Rubio, E. De Miguel, E. Galíndez-Agirregoikoa, F. Sivera, C. Fernández-López, C. Galisteo, I. Ferraz-Amaro, L. Sanchez-Bilbao, M. Calderón-Goercke, J. L. Hernández Hernández, M. A. González-Gay, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:1789-1790
BackgroundPositron emission tomography (PET) is one of the tools available for the diagnosis of extracranial large-vessel vasculitis (1-5). Tocilizumab (TCZ) has shown efficacy in large-vessel vasculitis (LVV) including GCA. However, the improvement
Autor:
L. Sanchez-Bilbao, J. Loricera, S. Castañeda, C. Moriano, J. Narváez, V. Aldasoro, O. Maiz, R. Melero, I. Villa-Blanco, P. Vela-Casasempere, S. Romero-Yuste, J. L. Callejas-Rubio, E. De Miguel, E. Galíndez-Agirregoikoa, F. Sivera, C. Fernández-López, C. Galisteo, I. Ferraz-Amaro, J. Sanchez-Martin, M. Calderón-Goercke, J. L. Hernández, M. A. González-Gay, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:379.2-380
BackgroundTocilizumab (TCZ) has shown efficacy in large-vessel vasculitis, including Giant Cell Arteritis (GCA) (1-3). Clinical trials with TCZ in GCA was performed with intravenous (iv) TCZ in a phase 2 trial (3), and with subcutaneous (sc) TCZ in t
Autor:
L. Sanchez-Bilbao, J. Loricera, C. Moriano, S. Castañeda, I. Ferraz-Amaro, J. Narváez, V. Aldasoro, O. Maiz, R. Melero, I. Villa-Blanco, P. Vela-Casasempere, S. Romero-Yuste, J. L. Callejas-Rubio, E. De Miguel, E. Galíndez-Agirregoikoa, F. Sivera, C. Fernández-López, C. Galisteo, J. Sanchez-Martin, M. Calderón-Goercke, J. L. Hernández, M. A. González-Gay, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:688.2-689
BackgroundVisual involvement is the most feared complication of Giant Cell Arteritis (GCA) (1-5). Permanent visual loss (PVL) may be preceded by transient visual loss. Once blindness is established, the prognosis is poor. Most of the series of predic
Autor:
C. Álvarez-Reguera, M. Calderón-Goercke, J. Loricera, C. Moriano, S. Castañeda, J. Narváez, V. Aldasoro, O. Maiz, R. Melero, I. Villa-Blanco, P. Vela-Casasempere, S. Romero-Yuste, J. L. Callejas-Rubio, E. De Miguel, E. Galíndez-Agirregoikoa, F. Sivera, C. Fernández-López, C. Galisteo, I. Ferraz-Amaro, J. Sanchez-Martin, L. Sanchez-Bilbao, J. L. Hernández Hernández, M. Á. González-Gay, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:692.2-693
BackgroundTocilizumab (TCZ) has shown to be useful in the treatment of large-vessel vasculitis, including giant cell arteritis (GCA) (1-4). There is general agreement on the initial and the standard maintenance dose of TCZ. However, information on du
Autor:
P. Fanlo, M. J. Ángel Torres, J. L. Callejas-Rubio, S. Pérez Ortega, Á. Robles Marhuenda, L. Pallares Ferreres, T. C. Salman Monte, Maria Luisa Galindo
Publikováno v:
Annals of the Rheumatic Diseases. 80:179.1-179
Background:Despite great advances in the diagnosis and treatment of lupus, the scientific community does not know the perception of our patients regarding the knowledge of the disease and the relationship between patients and disease. Fatigue had the